Curevo, a Seattle, WA-based clinical-stage biotechnology firm, raised $110M in Collection B funding.
The spherical was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus current traders RA Capital Administration, Janus Henderson Buyers, Adjuvant Capital, and founding investor GC Biopharma. Concurrent with the spherical, Moncef Slaoui, PhD, will be a part of Curevo as Board Chair. Additionally becoming a member of Curevo’s Board of Administrators shall be Giovanni Mariggi, PhD, co-founder and Accomplice at Medicxi. Tal Zaks, MD/PhD, shall be becoming a member of the Board on behalf of OrbiMed.
The corporate intends to make use of the funds to speed up the extension of its Part 2 program into an extra 640 contributors, together with the important thing inhabitants of adults over age 70, to finalize dose choice forward of the Part 3 program.
Led by CEO George Simeon, Curevo is a clinical-stage biotechnology firm devoted to creating vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to forestall shingles, a severe medical situation involving a painful, blistering pores and skin rash the place 10-18% of individuals additionally develop severe, long-lasting nerve ache.
FinSMEs
17/03/2025
